AP-SA02 Receives Breakthrough Therapy Designation

Company Armata Pharmaceuticals Event Type Regulatory Designation (FDA Breakthrough Therapy Designation) Modality Bacteriophage Therapy (fixed multi-phage cocktail) Asset AP-SA02 Target Staphylococcus aureus (methicillin-sensitive and methicillin-resistant) Disease Area Complicated S. aureus Bacteremia Summary The FDA granted Breakthrough Therapy designation to intravenous AP-SA02 as an adjunct to…